Actively Recruiting
Human Umbilical Cord Mesenchymal Stem Cell Transplantation for The Treatment of Acute-on-Chronic Liver Failure
Led by Beijing 302 Hospital · Updated on 2024-05-07
150
Participants Needed
1
Research Sites
274 weeks
Total Duration
On this page
Sponsors
B
Beijing 302 Hospital
Lead Sponsor
S
Shulan (Hang Zhou) Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is a randomized double-blind placebo-controlled multicenter clinical trial to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell (UC-MSC) transplantation for the treatment of acute-on-chronic liver failure (ACLF). UC-MSC therapy may improve the clinical outcomes of patients with ACLF. The trial would provide scientific evidence for UC-MSC transplantation as a potential treatment for ACLF.
CONDITIONS
Official Title
Human Umbilical Cord Mesenchymal Stem Cell Transplantation for The Treatment of Acute-on-Chronic Liver Failure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 70 years
- Diagnosis of acute-on-chronic liver failure (ACLF) by APASL criteria, including recent liver injury with jaundice (total bilirubin 25 mg/dL) and coagulopathy (INR 1.5 or prothrombin activity <40%), with ascites or encephalopathy within 4 weeks
- Willingness to sign informed consent
You will not qualify if you...
- Acute kidney injury, upper gastrointestinal bleeding, hepatic encephalopathy grade II or higher, or uncontrolled infection at baseline
- Platelet count less than 50 x 10^9/L or Child-Pugh score greater than 9 before liver failure
- Liver cancer or other malignant tumors
- Previous liver transplant or planned liver transplant within 3 months
- Severe disease of major non-liver organs
- History of venous thrombosis or pulmonary embolism judged unsuitable by investigator
- Pregnant, breastfeeding, or planning pregnancy soon
- Known severe allergies or history of severe allergic reactions
- Immunosuppressant or immune enhancer treatment within 1 month
- Drug abuse in past 5 years
- Alcohol withdrawal symptoms
- Severe mental disorders in past 24 months, including uncontrolled depression or psychosis
- Participation in other clinical trials within 3 months or prior stem cell therapy
- Other conditions deemed unsuitable by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
the Fifth Medical Center, Chinese PLA General Hospital
Beijing, Beijing Municipality, China, 100039
Actively Recruiting
Research Team
T
Tao Yang, MD
CONTACT
Y
Yanhu Wang, MM
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here